Skip to content Skip to footer
Subscribe Now
INSIGHTS+ TOP 20

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025) 

Shots:  PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics.   The report tracks the rise and fall of leading biopharma companies over two decades driven by…
July 10, 2026

Read more

MAGAZINE

PharmaShots Magazine-July-2026 Edition

Shots: This edition explores AI-Powered Pharmaceutical Logistics, highlighting how artificial intelligence, predictive analytics, robotics, IoT, and digital twins are transforming pharmaceutical supply chains into intelligent, resilient, and patient-centric networks that optimize forecasting, manufacturing, warehousing, and global distribution. Through expert perspectives, feature stories, and regulatory insights, we examine the opportunities and challenges of AI-enabled pharmaceutical logistics—from…
July 9, 2026

Read more

INSIGHTS+

Q2 in Review: Pharma’s Dealmaking Surge, a Wave of FDA Approvals, and AI’s Deepening Footprint 

A PharmaShots Quarterly Analysis  Q2 was one of the most active quarters in recent memory for the pharmaceutical and biotech industry. Big Pharma leaned hard into M&A and licensing to refill pipelines, the FDA cleared a broad slate of new therapies, and AI-native partnerships continued to reshape how drugs get discovered. Below, we break down the quarter…
July 2, 2026

Read more

CXO TALKS

CXO Talks Podcast | The Road to Acquisition: Oncolytics’ CEO Jared Kelly on Clinical Data, IP & Pharma Partnerships

Shots: In an engaging conversation with PharmaShots CXO Talks, Jared Kelly, CEO & Director of Oncolytics Biotech, shared insights from his experience leading corporate strategy at Ambrx and contributing to its $2B acquisition by Johnson & Johnson, offering a practical perspective on what makes biotech companies attractive acquisition targets. Kelly explained why successful biotech acquisitions…
June 24, 2026

Read more

EVENTS

HLTH Europe 2026: Key Highlights & Industry Insights 

Shots  • HLTH Europe 2026 brought together over 5,000 healthcare leaders, investors, policymakers, payers, providers, pharmaceutical executives, and digital health innovators in Amsterdam to explore the future of healthcare innovation.  • Healthcare has a paradox: brilliant point solutions are failing not because they don't work, but because they can't talk to each other. A patient…
June 22, 2026

Read more

VIEWPOINTS

Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy  

Shots:  PulseSight Therapeutics is advancing a novel approach to Geographic Atrophy (GA) with PST-611, a first-in-class non-viral gene therapy designed to restore iron homeostasis by targeting transferrin biology—an upstream driver of retinal degeneration.  At ARVO 2026, PST-611 delivered encouraging Phase I results, demonstrating an excellent safety and tolerability profile, stable visual acuity, and early signals of potential functional…
June 22, 2026

Read more

MAGAZINE

PharmaShots Magazine-June-2026 Edition

Shots: This edition explores Digital Vigilance: AI Enhancing Post-Market Safety Monitoring, highlighting how artificial intelligence, real-world data, and digital listening technologies are transforming pharmacovigilance into a proactive, predictive, and patient-centric discipline. Through expert perspectives, cover stories, and regulatory insights, we examine the opportunities and challenges of AI-driven safety surveillance—from social media signal detection and real-world…
June 11, 2026

Read more

VIEWPOINTS

Jared Kelly on Immune Priming & Survival Outcomes: Oncolytics Biotech’s Vision for Pelareorep

Shots:  Oncolytics Biotech is advancing pelareorep beyond the traditional standalone therapy model, positioning the platform as a potential immune-priming backbone capable of enhancing immunotherapies, checkpoint inhibitors, chemotherapies, and other oncology treatments across multiple difficult-to-treat tumor settings.  The company continues generating growing survival and immune-engagement data across colorectal, pancreatic, and anal cancers, while emphasizing pelareorep’s potential to “turn cold tumors…
June 3, 2026

Read more

VIEWPOINTS

Advancing HES Care with AstraZeneca’s FASENRA: Insights from James Teague & Princess U. Ogbogu

Shots:  Could a targeted biologic therapy help address the longstanding unmet needs in hypereosinophilic syndrome (HES)? AstraZeneca’s FASENRA has now received US approval for HES, introducing a once-monthly treatment option for patients living with this rare and often underdiagnosed eosinophilic disorder  Results from the Phase III NATRON trial showed that FASENRA reduced the risk of first HES flare by 65% vs placebo,…
June 1, 2026

Read more

EVENTS

2026 HLTH Europe | June 15-18 | Amsterdam

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful launch and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe’s unique healthcare challenges and opportunities. Unlock an exclusive €250 discount with PharmaShots! Use code HE26PHARMASHOTS at checkout to save…
May 14, 2026

Read more

Load more